Carbamate derivatives of colchicine show potent activity towards primary acute lymphoblastic leukemia and primary breast cancer cells—in vitro and ex vivo study
- 5 March 2020
- journal article
- research article
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 34 (6) , e22487
Abstract
Colchicine (COL) shows strong anticancer activity but due to its toxicity towards normal cells its wider application is limited. To address this issue, a library of 17 novel COL derivatives, namely N‐carbamates of N‐deacetyl‐4‐(bromo/chloro/iodo)thiocolchicine, has been tested against two types of primary cancer cells. These included acute lymphoblastic leukemia (ALL) and human breast cancer (BC) derived from two different tumor subtypes, ER+ invasive ductal carcinoma grade III (IDCG3) and metastatic carcinoma (MC). Four novel COL derivatives showed higher anti‐proliferative activity than COL (IC50 = 8.6 nM) towards primary ALL cells in cell viability assays (IC50 range of 1.1‐6.4 nM), and several were more potent towards primary IDCG3 (IC50 range of 0.1 to 10.3 nM) or MC (IC50 range of 2.3‐9.1 nM) compared to COL (IC50 of 11.1 and 11.7 nM, respectively). In addition, several derivatives were selectively active toward primary breast cancer cells compared to normal breast epithelial cells. The most promising derivatives were subsequently tested against the NCI panel of 60 human cancer cell lines and seven derivatives were more potent than COL against leukemia, non–small‐cell lung, colon, CNS and prostate cancers. Finally, COL and two of the most active derivatives were shown to be effective in killing BC cells when tested ex vivo using fresh human breast tumor explants. The present findings indicate that the select COL derivatives constitute promising lead compounds targeting specific types of cancer.Keywords
Funding Information
- Polish Science Centre (2016/21/B/ST5/00111)
- Arkansas Breast Cancer Research Program
This publication has 36 references indexed in Scilit:
- Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell linesBMC Cancer, 2012
- ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial CellsThe American Journal of Pathology, 2012
- Cell line cross‐contamination initiative: An interactive reference database of STR profiles covering common cancer cell linesInternational Journal of Cancer, 2009
- Long–term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factorsExperimental Hematology, 2009
- Enhancement of Docetaxel Anticancer Activity by a Novel Diindolylmethane Compound in Human Non–Small Cell Lung CancerClinical Cancer Research, 2009
- Colchicine inhibits pressure-induced tumor cell implantation within surgical wounds and enhances tumor-free survival in miceJournal of Clinical Investigation, 2008
- Anti‐mitotic activity of colchicine and the structural basis for its interaction with tubulinMedicinal Research Reviews, 2007
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- The Cell Cycle and Regulation of Cancer Cell GrowthAnnals of the New York Academy of Sciences, 1996
- Inhibition of prostate cancer growth by estramustine and colchicineThe Prostate, 1995